

Indian Immunologicals working on bi-valent human monoclonal antibody for rabies

The mAb is being developed with support from the National Biopharma Mission of the department of biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC), the Hyderabad-based vaccine maker said on Saturday.



Hyderabad: Vaccine maker Indian Immunologicals Ltd (IIL) is developing a bi-valent monoclonal antibody (mAb) of human origin for rabies.

The mAb is being developed with support from the

National Biopharma Mission of the department of biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC), the Hyderabad-based vaccine maker said on Saturday.

“This fully human monoclonal antibody has the potential to revolutionize rabies management, offering a highly effective and targeted therapy for post-exposure prophylaxis. This breakthrough innovation will mark a significant milestone in global efforts to control and prevent rabies,” said IIL managing director Dr K Anand Kumar.

RFXC_GfPpV28R0G333U_CfRQ3b2Emtxcip1Wq4HjJ8gAvYaNZSdpRm_Frqv

IIL, which is a wholly owned subsidiary of National Dairy Development Board (NDDB), claims to be the largest manufacturer of rabies vaccine globally with a capacity to manufacture 30 million doses per annum of its Abhayrab anti-rabies vaccine.

The IIL MD said rabies remains a major public health concern in India, which accounts for nearly 36 per cent of global rabies deaths.

“Despite being a preventable disease, rabies still claims thousands of lives each year. Over 40 per cent of those who are bitten by potentially rabid animals are children under the age of 15. With growing urbanisation and increasing stray dog population, the risk of animal bites continues to rise, emphasising the need for enhanced public awareness and preventive measures,” he said.

He pointed out that by developing innovative products like monoclonal antibodies and continued efforts to raise public awareness, IIL is focused on saving lives and reducing the burden of rabies in India and globally.

News Source:

<https://pharma.economictimes.indiatimes.com/news/research-and-development/indian-immunologicals-working-on-bi-valent-human-monoclonal-antibody-for-rabies/113779718>